AstraZeneca

Cullgen Inc. is a biopharmaceutical company based in San Diego, California, established in 2018. The company focuses on developing innovative new chemical entities (NCEs) aimed at treating diseases that currently lack effective therapeutic options. Utilizing its proprietary uSMITE™ platform, Cullgen employs targeted protein degradation technology to selectively degrade disease-causing proteins. This approach is particularly significant for addressing cancer, inflammatory, and autoimmune diseases, including targets that have been deemed undruggable. By providing novel therapeutic strategies, Cullgen aims to enhance drug discovery and offer new avenues for treating debilitating conditions.

Axbio Inc. is a biotechnology company based in Shenzhen, China, specializing in the development and manufacturing of advanced genetic sequencing technology and diagnostic equipment. Founded in 2016, the company offers a variety of genome extraction kits, including those for stool, blood, saliva, and bacteria. Axbio's product line also encompasses sequencing and diagnostic systems, disposable biochips, and reagents. The company employs semiconductor nanotechnology in its biochips for rapid molecular in-vitro diagnostics and utilizes a microfluidic Bio-CMOS platform for high-throughput sequencing. Axbio's capabilities extend from low-cost handheld devices for bedside diagnostics to fully automated instruments suitable for independent laboratories and hospitals, facilitating services such as early cancer screening, rapid pathogen detection, and drug development. The company is currently operating in stealth mode.

Yueer is a genomics company driven by technology, with a number of revolutionary molecular detection technologies that can reduce the sequencing cost of all NGS platforms and the sensitivity of qPCR, Sanger, and nanopore sequencing. Yueer Gene collaborates with many partners to develop affordable, timely, and accurate genetic analysis tools in order to achieve precision medicine and improve patient outcomes.

Huma Therapeutics Limited is a healthcare technology company based in London, United Kingdom, focused on improving the lives of individuals with chronic, complex, and rare diseases. The company operates a healthcare platform that integrates patient data from various medical databases and devices, making it accessible to healthcare professionals. One of its key offerings is Medopad, a remote patient monitoring platform that allows doctors to oversee patients with conditions such as Covid-19 without the need for hospital admission. Huma collaborates with leading healthcare providers, pharmaceutical companies, insurers, and technology firms, including Apple and Tencent, to create a connected digital health ecosystem. Founded in 2011 and rebranded from Humaforhealth Limited in April 2020, Huma continues to expand its impact in the healthcare sector.

Creativity (Beijing) Medical Technology Development Co., Ltd. is a leading minimally invasive interventional delivery system product full solution provider. Committed to cooperating with top experts at home and abroad in the field of minimally invasive intervention, and cooperating with internationally renowned raw material manufacturers to jointly develop, produce and sell leading products. Provide doctors with differentiated diagnosis and treatment tools, relieve patients' pain and reduce medical burden.

Cellular Biomedicine Group is a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. It is the result of the acquisition, transfer, commercialization, and advancement of thirty years of research and human treatment experience in cellular medicine. Its cellular research and development is the result of collaboration among scientists and doctors from the US, England, and China.

Alexion Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing biologic therapies for severe and life-threatening conditions, including hematologic, kidney, and neurologic diseases, as well as transplant rejection, cancer, and autoimmune disorders. One of its primary products is Soliris (eculizumab), a therapy approved for treating paroxysmal nocturnal hemoglobinuria (PNH). The U.S. Food and Drug Administration and the European Commission granted Soliris orphan drug designation for atypical hemolytic uremic syndrome (aHUS) in 2009. Additionally, Alexion's manufacturing facility in Rhode Island received regulatory approval from the European Commission for the production of Soliris in December 2009. The company is recognized as a leader in delivering treatments for patients with rare and devastating diseases.

OnDosis AB develops and manufactures handheld dosing device. The company's product connects and enables patients to digital health services, including, treatment. The company was founded in 2017 and is headquartered in Gothenburg, Sweden.

ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Our ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superior therapeutic index compared to first- generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.

Innate Pharma S.A. is a clinical-stage biotechnology company based in Marseille, France, focused on developing therapeutic antibodies for oncology and inflammatory diseases. The company specializes in immunotherapies that leverage the innate immune system, particularly through its proprietary ANKET platform, which facilitates the creation of novel monoclonal antibodies. Innate Pharma's product pipeline includes several candidates in various stages of clinical development, such as Monalizumab, an immune checkpoint inhibitor for advanced solid tumors, and Lacutamab, an anti-KIR3DL2 antibody for cutaneous T-cell lymphoma. Other notable candidates include Avdoralimab, a therapeutic antibody targeting C5a receptors, and IPH5201, which aims to block the CD39 immunosuppressive pathway. Additionally, the company has formed strategic collaborations and licensing agreements with major pharmaceutical firms, enhancing its research capabilities and market reach. Founded in 1999, Innate Pharma continues to advance its innovative approaches to cancer treatment.

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, focused on developing innovative therapies for cardiopulmonary diseases. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor and is currently undergoing Phase III clinical trials for patients experiencing uncontrolled bleeding or requiring urgent surgery. The company is also advancing PB1046, a fusion protein aimed at treating pulmonary arterial hypertension, which is in Phase IIb clinical trials. Additionally, PhaseBio is developing PB6440, an oral agent intended for the treatment of resistant hypertension. Founded in 2002, the company leverages proprietary recombinant biopolymers to enhance the stability and efficacy of its drug candidates.

Viela Bio, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, focused on developing treatments for severe inflammation and autoimmune diseases. Its lead product candidate, inebilizumab, is a humanized monoclonal antibody targeting CD19, aimed at treating conditions such as neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. The company is also advancing additional candidates, including VIB4920 for kidney transplantation rejection and Sjögren’s syndrome, as well as VIB7734 for cutaneous lupus erythematosus. Viela Bio has formed a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases across several countries in Asia. Founded in 2017, the company is dedicated to addressing unmet medical needs in the field of autoimmune disorders.

Rani Therapeutics, LLC, founded in 2012 and based in San Jose, California, specializes in developing oral biotherapeutics technologies for the delivery of large drug molecules, such as peptides, proteins, and antibodies. The company aims to provide a convenient alternative to traditional injection methods through its proprietary RaniPill capsule, which is designed to facilitate the oral administration of biologics. Rani Therapeutics offers a range of treatments targeting various health conditions, including TNF-alpha inhibitors for inflammatory disorders, parathyroid hormone for osteoporosis, and human growth hormone for growth deficiencies. Additionally, the company develops therapies for multiple sclerosis, type II diabetes, obesity, and other inflammatory diseases using its innovative oral delivery system.

ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Our ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superior therapeutic index compared to first- generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.

Rani Therapeutics, LLC, founded in 2012 and based in San Jose, California, specializes in developing oral biotherapeutics technologies for the delivery of large drug molecules, such as peptides, proteins, and antibodies. The company aims to provide a convenient alternative to traditional injection methods through its proprietary RaniPill capsule, which is designed to facilitate the oral administration of biologics. Rani Therapeutics offers a range of treatments targeting various health conditions, including TNF-alpha inhibitors for inflammatory disorders, parathyroid hormone for osteoporosis, and human growth hormone for growth deficiencies. Additionally, the company develops therapies for multiple sclerosis, type II diabetes, obesity, and other inflammatory diseases using its innovative oral delivery system.

Ethris GmbH is a biotechnology company based in Planegg, Germany, specializing in the development of innovative therapeutic solutions for diseases with unmet medical needs. The company has a focus on transcript therapeutics, particularly through its SNIM RNA platform, which offers a novel approach to treating various conditions by enabling the production of therapeutic proteins within the patient’s body. This platform presents an alternative to traditional recombinant protein and gene therapies, addressing a range of diseases, including rare and genetically predetermined conditions. Ethris also develops Magnetovax, a personalized tumor vaccine platform that utilizes magnetic fields for localized activation in tumors. The company has established strategic research collaborations with major pharmaceutical firms, enhancing its capabilities in regenerative medicine and therapeutic development. Founded in 2009, Ethris continues to advance its technologies to meet diverse medical needs.

ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Our ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superior therapeutic index compared to first- generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.

Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2010. It specializes in the development of therapeutics and vaccines utilizing messenger RNA technology, which instructs cells to produce proteins essential for various biological functions. The company's extensive pipeline includes 40 mRNA development candidates targeting a range of therapeutic areas such as infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders. Moderna gained significant recognition with its COVID-19 vaccine, which was authorized for use in the United States in December 2020. The company maintains strategic partnerships with organizations such as AstraZeneca, Merck & Co., and the Bill & Melinda Gates Foundation, enhancing its research capabilities and manufacturing processes. Additionally, it has research collaborations with esteemed institutions like Harvard University.

FibroGen, Inc. is a biopharmaceutical company based in San Francisco, California, with additional offices in Beijing and Shanghai. The company specializes in discovering, developing, and commercializing therapeutics aimed at addressing serious unmet medical needs, particularly in the areas of anemia, fibrotic diseases, and cancer. Its lead product, Roxadustat, is an oral small-molecule inhibitor currently undergoing Phase III clinical trials for the treatment of anemia in chronic kidney disease in the United States and Europe, and is also being evaluated in China for myelodysplastic syndromes. Additionally, FibroGen is developing Pamrevlumab, a human monoclonal antibody that targets connective tissue growth factor, which is in Phase III trials for conditions such as idiopathic pulmonary fibrosis and pancreatic cancer, as well as in Phase II trials for Duchenne muscular dystrophy. The company has established collaboration agreements with partners like Astellas Pharma and AstraZeneca to enhance its research and development efforts.

Takeda defined four therapeutic areas of focus: Gastroenterology, Oncology, Central Nervous System, and Cardiovascular and Metabolic.

Acerta Pharma B.V. offers drug discovery and development services for oncology and autoimmune diseases. It offers late stage development, and early stage development. The company was founded in 2013 and is based in Oss, the Netherlands. Acerta Pharma B.V. operates as a subsidiary of AstraZeneca PLC.

ZS Pharma, Inc. is a biopharmaceutical company based in Coppell, Texas, focused on developing non-absorbed drugs for renal, cardiovascular, liver, and metabolic diseases. Established in 2008, the company specializes in highly selective ion-trap therapies, particularly its lead candidate, ZS-9. This innovative treatment employs proprietary zirconium silicate technology to create ion traps that can effectively reduce excess potassium levels in patients suffering from hyperkalemia, a serious condition often associated with chronic kidney disease, hypertension, diabetes, and heart failure. ZS-9 is currently undergoing late-stage clinical trials to evaluate its efficacy and safety. As of December 2015, ZS Pharma operates as a subsidiary of Zeneca, Inc.

ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Our ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superior therapeutic index compared to first- generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, focused on developing innovative therapies for cardiopulmonary diseases. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor and is currently undergoing Phase III clinical trials for patients experiencing uncontrolled bleeding or requiring urgent surgery. The company is also advancing PB1046, a fusion protein aimed at treating pulmonary arterial hypertension, which is in Phase IIb clinical trials. Additionally, PhaseBio is developing PB6440, an oral agent intended for the treatment of resistant hypertension. Founded in 2002, the company leverages proprietary recombinant biopolymers to enhance the stability and efficacy of its drug candidates.

Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2010. It specializes in the development of therapeutics and vaccines utilizing messenger RNA technology, which instructs cells to produce proteins essential for various biological functions. The company's extensive pipeline includes 40 mRNA development candidates targeting a range of therapeutic areas such as infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders. Moderna gained significant recognition with its COVID-19 vaccine, which was authorized for use in the United States in December 2020. The company maintains strategic partnerships with organizations such as AstraZeneca, Merck & Co., and the Bill & Melinda Gates Foundation, enhancing its research capabilities and manufacturing processes. Additionally, it has research collaborations with esteemed institutions like Harvard University.

MdBio Foundation, Inc. has been providing innovative and effective bioscience education for middle and high school students since 1997. The non-profit, (501 c 3) organization is dedicated to providing bioscience awareness, education, and workforce development in the state of Maryland and beyond. The Foundation accomplishes this through a diverse set of programs, including their flagship program, MdBioLab, summer programs, and their leading-edge game-based learning platform, MdBioSphere. MdBio Foundation leverages its established, trusted relationships with private industry and school systems to create authentic, STEM-based career experiences on their mobile laboratory, MdBioLab, and through their youth camp, the Young Science Explorers Program (YSEP). These experiences provide a unique opportunity for students to observe first hand the types of careers they could pursue in STEM-related fields. Students and teachers who participate in MdBioLab and YSEP have increased access to information about bioscience industry products, research, and related careers through problem-based laboratory experiences that are aligned with local, state and, national curriculum standards. Commitment to Excellence: Since its inception, The MdBio Foundation has contributed more than $3.5M of their resources to these programs and will continue to invest more than $500K each year. The Foundation’s staff consists of talented and experienced educators and scientists who share a common goal of improving science education and creating a more accessible, educational experience.

Almirall, S.A. is an international pharmaceutical company headquartered in Barcelona, Spain, focused on the research, development, manufacture, and sale of medicines primarily related to skin health. The company offers a range of products for various dermatological conditions, including actinic keratosis, atopic dermatitis, psoriasis, acne, and other diseases, as well as treatments for central nervous system, cardiovascular, and gastrointestinal disorders. Almirall's product portfolio includes well-known medications such as Actikerall, Solaraze, and Ilumetri. To enhance its research capabilities, the company has established collaborations with organizations like Evotec AG, X-Chem, and the University of Dundee, focusing on innovative therapeutics and new drug design. Founded in 1943, Almirall has evolved from its original name, Laboratorios Almirall, to its current designation in 2009, while maintaining a commitment to improving health and well-being through innovation.

Allegiance Health is a community-owned, locally-governed health system in Jackson, Michigan. We combine hospital-based care with a full range of services for all members of our community. Allegiance is a leader in forming community partnerships which innovatively address wellness and preventative needs. We are proudly entering our 10th decade of serving the people of south central Michigan with local, high-quality care.Comprised of more than 40 different facilities, Allegiance reaches the residents of Jackson, Hillsdale, Lenawee, Ingham, Calhoun and Washtenaw counties and beyond. Wherever we are in the region, our mission remains constant. We lead our community to better health and well-being at every stage of life. Our vision is to create Michigan’s healthiest community through exceptional health care and inspiring a passion for wellness.

Established in 1996, Catherine’s Health Center is a 501(c)(3) safety net medical clinic, serving more than 6,000 patients annually. Using a small core of paid staff and many dedicated volunteers, Catherine’s mission is to provide free or low-cost medical services to low-income, uninsured and underinsured residents of Kent Count.Catherine’s Health Center is a non-profit community-based health facility dedicated to serving low-income, uninsured residents of the northeast sections of Grand Rapids, Michigan, primarily those who live in the Creston and Belknap neighborhoods. Supporting the center’s activities are a governing board and group of volunteers working to make health care available to those in need.

North Georgia Healthcare Center is a non-profit health care center in Ringgold, Georgia. NGHCC is federally funded by the U.S.D.A. Direct Loan Program funds. The organization will seek sponsorship through private corporations, community, and grants and it will accept Private Insurance, Medicare, Medicaid. NGHCC will offer medical services to North Georgia and surrounding areas seven days a week with extended hours.

Elkhorn Logan Valley Public Health Department was created in 2002 to serve the citizens and communities of Burt, Cuming, Madison and Stanton counties. Located in Wisner, Nebraska, with a satellite office in Norfolk, the department focuses on healthy lifestyle management and disease prevention with over 20 programs initiated to maximize wellness and safety.

UnityPoint Health is a nonprofit health system based in the United States, recognized as one of the country's most integrated healthcare networks. Founded in 1993, it operates more than 280 physician clinics and 30 hospitals across metropolitan and rural areas in Iowa and Illinois. The organization emphasizes coordinated patient care, facilitating communication among healthcare professionals to ensure appropriate treatment settings, whether in clinics, hospitals, or home care. Each year, UnityPoint Health manages over 4 million patient visits, delivering a comprehensive range of services to individuals and families. With annual revenues of $2.7 billion, it ranks as the 13th largest nonprofit health system in the nation and the fourth largest among nondenominational systems.

Ashland-Boyd County Health Department is located in the Appalachian highlands of eastern Kentucky where the state lines of Kentucky, Ohio and West Virginia meet. Our mission, “To improve the quality of life for all who live, work and play in Boyd County through disease prevention, health promotion, environmental safety and public health preparedness,” is rooted in our long and proud history of serving the residents of our small, yet vibrant community.

Matthew Walker Comprehensive Health Center, Inc. provides healthcare and health education services. It provides pediatric care, family and internal medicine, general dentistry, ophthalmology, geriatrics, obstetrics and gynecology, nutrition, mental health, pharmacy, radiology, and diagnostic laboratory testing and screening services. The company was founded in 1968 and is based in Nashville, Tennessee.

Sankofa Community Development Corporation, established in 2008, is a nonprofit organization focused on revitalizing the Lower and Upper Ninth Ward communities of New Orleans. It aims to enhance urban living through various initiatives that promote healthy lifestyles, youth empowerment, and education. Key projects include the Sankofa Mobile Market, which provides access to fresh produce, the Sankofa HEAL Project, which emphasizes health education, and the Sankofa Learning Gardens and Farms Project, which fosters intergenerational learning and community engagement. Through these efforts, Sankofa Community Development seeks to create a safer, more stable, and sustainable environment for lower middle-class residents in the area.

UCHealth is a not-for-profit healthcare organization founded in 1925 and based in northern Colorado. It serves a broad region that includes Colorado, Nebraska, and Wyoming, covering over 50,000 square miles. The organization operates as a regional medical hub, comprising facilities such as Poudre Valley Hospital, Medical Center of the Rockies, and Mountain Crest Behavioral Health Center, along with numerous clinics and outpatient services. UCHealth is dedicated to providing high-quality, evidence-based care and wellness services, with a mission to improve lives through a combination of academic and community-focused medicine. The organization emphasizes innovation in healthcare while maintaining strong connections with the communities it serves.

The Health Wagon is a nonprofit 501(c)(3) organization providing mobile health services to the medically underserved in southwest Virginia since 1980. The Health Wagon’s mission is to provide compassionate, quality healthcare to the medically underserved in the mountains of Appalachia. The Health Wagon visits 10 sites in six counties – Buchanan, Dickenson, Lee, Russell, Scott and Wise counties – to serve a severely medically underserved population. The Health Wagon currently has two mobile health units and two stationary clinics servicing southwest Virginia.

Whittier Street Health Center (WSHC) is a comprehensive, innovative and high quality health care and wellness center championing equitable access to high quality, cost-effective health care for diverse populations. WSHC is accredited by The Joint Commission (TJC), certified by the NCQA as a golden level (highest ranking) patient centered medical home and licensed by the Massachusetts Department of Public Health (DPH). The vision of the Whittier Street Health Center is to serve as the premiere health center for Boston residents and the mission is to provide high quality, reliable and accessible primary care and support services to promote wellness and eliminate health and social disparities. Located in the Roxbury neighborhood of Boston, Whittier Street Health Center provides comprehensive health services including primary care, behavioral health care, substance abuse services, dental care and eye care to over 25,000 patients. A trusted member of the community for 80 years, Whittier is here to provide the care that you and your family need to get healthy and stay healthy. We provide many services to help raise it out of poverty and into a place of good health. Having translators for 17 languages and utilizing clinical and social services to meet specific community needs through outreach, targeted programs and state of the art health care delivery helps us stay connected with the community.

Manna Ministries has a longstanding commitment to fiscal responsibility and is audited each year by an independent CPA firm. Our audits reveal that 96% of our funding goes directly to support our programs, while only 4% goes to administrative costs. Partnerships allows us to help more people lead healthier lives by providing them with the basic necessities of life such as food, shelter, and healthcare.

Dr. Arenia C. Mallory Community Health Center (MCHC) is named to honor the memory of Dr. Arenia C. Mallory, well known educator and champion of human causes. She inspired young minds regardless of their race, economic or social status to “Walk in Dignity, Talk in Dignity, and Live in Dignity”.

The Food Trust, a nonprofit founded in 1992, strives to make healthy food available to all. Working with neighborhoods, schools, grocers, farmers and policymakers, we've developed a comprehensive approach that combines nutrition education and greater availability of affordable, healthy food.

Based in Wilmington, DE, Christiana Care Health System is one of the largest health care providers in the mid-Atlantic region, serving all of Delaware and parts of Pennsylvania, Maryland and New Jersey. We are a not-for-profit teaching health system that includes two hospitals with more than 1,100 patient beds, a home health care service, preventive medicine, rehabilitation services, a network of primary care physicians and an extensive range of outpatient services. Christiana Care is recognized as a regional center for excellence in cardiology, cancer, orthopaedics and women's health services, as well as for its Level-I trauma care and Level-3 neonatal intensive care (both highest capability).

Nektar Therapeutics is a biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. Nektar also partners with the top biopharmaceutical companies to bring new products to market. To date, Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.

Pearl Therapeutics is a private company focused on developing dual and triple combination therapies for prevalent respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), asthma, and rhinosinusitis. The company aims to enhance patient care by providing advanced inhaled therapies through familiar metered dose inhalers. Led by an experienced team specializing in respiratory product development, Pearl Therapeutics is dedicated to creating alternatives that improve safety and efficacy compared to existing treatments, ultimately striving for better clinical outcomes for patients and healthcare providers.

Omthera Pharmaceuticals, Inc. is a specialty pharmaceuticals company dedicated to the clinical development of new therapies for dyslipidemia, a condition characterized by elevated triglyceride levels that increases the risk of cardiovascular disease. The company is led by a team of experienced professionals in the field of lipid disorders, focusing on creating innovative treatments aimed at improving the health and quality of life for millions of affected patients. By concentrating on this specific area of healthcare, Omthera aims to address the unmet medical needs of individuals suffering from dyslipidemia and contribute to better management of cardiovascular risk.

Operator of a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases. The company's lead product candidate for the treatment of hyperuricemia and gout, RDEA594, is a selective URAT1 transporter inhibitor in Phase 2 clinical development.

Guangdong BeiKang Pharmaceutical Company Ltd manufactures drugs which includes generic injectable antibiotics.

Novexel is a pharmaceutical company that researches and develops novel class antiinfectives for the treatment of severe and difficult to treat bacterial and fungal infections. The Company has an extensive portfolio of antibacterial and anti-fungal compounds, R&D programs, and intellectual property. Novexel’s focus is on novel antimicrobial compounds with activity against multi-resistantorganisms. Novexel’s expertise in Biology, Medicinal Chemistry, Pharmacology, Microbiology and Clinical Development positions the Company at the forefront of the discovery and development of novel therapies for infectious disease.

Arrow Therapeutics was founded in 1998 and is already making a significant contribution to anti-infective drug discovery. Microbial resistance to existing drugs is an ever increasing threat that is leading to serious unmet medical need and incurring a huge financial burden on society. Despite the huge challenges of this situation it also presents excellent opportunities to combine scientific research and business. As more and more big pharma groups concentrate their efforts on drug development, greater chances are open to smaller companies such as ours to show their excellence in research.

Cambridge Antibody Technology was a biotechnology company headquartered in Cambridge, England.

KuDOS Pharmaceuticals Ltd discovers and develops drugs based upon the science of DNA damage sensing, signaling, and repair to address medical needs in cancer treatment.